PSA is a validated FDA-recognized clinical endpoint in assessing prostate cancer treatment response; Telomir-1 lowered PSA ...

Scientists have uncovered a critical weakness in prostate cancer’s defences. The disease relies on two enzymes, PDIA1 and PDIA5, to survive and resist treatment. When these enzymes are blocked, cancer ...

A new study has uncovered promising therapeutic strategies against one of the deadliest forms of prostate cancer.

Men diagnosed with prostate cancer have traditionally faced two choices: Do nothing and hope the tumor doesn’t grow between ...

Consider this a PSA about PSA. Prostate cancer is the most common cancer in US men, excluding skin cancer, and the second-leading cause of male cancer deaths, after lung cancer. One in 6 men will be ...

It sounds deceptively simple. Develop a better prostate cancer treatment by super charging the body's own natural killer ...

Medicus Pharma Ltd. (Nasdaq: MDCX) is a biotech/life sciences company focused on accelerating the clinical development programs of novel and potentially disruptive therapeutics assets. The Company is ...

The UK National Screening Committee (UK NSC) is due to say only men with the BRCA1 and BRCA2 mutations, aged between 45 and ...

Up to 85 percent of prostate cancers are diagnosed in the early stages, when they are still curable.Even when diagnosed at an advanced stage, most prostate cancers respond well to treatment. The first ...

There is currently no screening programme for prostate cancer, the most common cancer in men. But there has been some ...

There is no single, diagnostic test. Doctors make a diagnosis based on various measures. This can include a prostate-specific ...